Kopp Family Office Sells $3.5 Million Stake in Viridian Therapeutics
Kopp Family Office sold 117,878 shares of Viridian Therapeutics for an estimated $3.5 million, reducing its stake to 0.7% of AUM. The sale comes after the stock underperformed the S&P 500 by 28 percentage points over the past year. The transaction is reported in an SEC filing dated April 20, 2026.
Tickers: $VRDN
Topics: portfolio changes SEC filings stock transactions Viridian Therapeutics